Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Professor Jinchun Xing: Advances and Future Perspectives in the Diagnosis and Treatment of Urothelial Carcinoma | 2025 Pujiang Uro-Oncology Conference 

    Urothelial carcinoma (UC) is a highly aggressive malignancy with high incidence and severe complications, significantly impacting patients’ quality of life and survival outcomes. In recent years, there have been remarkable advances in both the diagnosis and treatment of UC. At the 2025 Pujiang Uro-Oncology Conference—jointly organized by the CSCO Urothelial Carcinoma Expert Committee, CSCO Renal…

    2025.09.18
  • Professor Zhuowei Liu: Pioneering a New Paradigm in Urothelial Carcinoma Treatment – From Surgical Innovations to Mechanistic Insights | 2025 Pujiang Uro-Oncology Conference 

    At the recently concluded 2025 Pujiang Uro-Oncology Conference, the “High-Quality Development Forum on Urologic Oncology” drew considerable attention as leading domestic and international experts shared cutting-edge clinical and translational research progress. Professor Zhuowei Liu from Sun Yat-sen University Cancer Center (SYSUCC) was invited to present his team’s series of innovative studies in the field of…

    2025.09.18
  • Professor Qing Zou: Advancing Comprehensive Therapy and “Full-Course Management” Systems for Urologic Malignancies

    In recent years, the management of urologic malignancies—including kidney cancer and bladder cancer—has been moving toward a new era of comprehensive care, innovative treatments, multidisciplinary collaboration (MDT), and multi-technology integration. The goal is to build a “full-course management” system that maximizes clinical benefit for patients by combining advances from across specialties. At the 2025 Pujiang…

    2025.09.18
  • Professor Yue Lu: Second Allogeneic Hematopoietic Stem Cell Transplantation for Post-Transplant Relapse in Acute Leukemia

    Editor’s Note: On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was successfully held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology…

    2025.09.17
  • Professor Francesca Lorraine Wei Inng Lim: The Cell Therapy Landscape in Singapore

    On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology & Rare Disease…

    2025.09.17
  • Professor Ceshi Chen’s Speech at COMB 2025

    2025.09.17
  • Professor Junfang Yang: Clinical Research and Practice of CD7 CAR-T Therapy in Relapsed/Refractory Hematologic Malignancies

    On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, co-hosted by the Beijing Health Promotion Association and the Guangzhou Hongmian Oncology & Rare Disease Public…

    2025.09.17
  • Professor Jiong Wu’s Speech at COMB 2025

    2025.09.17
«previous next»
Recent Posts
  • CSCO 2026 | Professor Yungan Tao: Perioperative Immunotherapy Combined with Local Treatment Is Reshaping the Head and Neck Cancer Treatment Landscape 
  • Growing Alongside CSCO | Professor Rui Ge: Gaining Knowledge and Friendship at CSCO While Exploring the Path to Precision Oncology 
  • CSCO: A Global Perspective | Leaders from ASCO, ESMO, and CSCO Convene to Discuss a New Landscape for Global Collaboration in Cancer Care 
  • Professor Wing Cheong Chow: Controversies, Risk-Stratified Pathways, and Localization of Breast Cancer Screening Strategies in Asia | 2026 Lingnan Breast Cancer Academic Forum
  • CSCO 2026 | Professor Qiang Wei: Real-World Evidence Further Validates the Clinical Benefits of Enzalutamide-Based Combination Therapy in Older, Frail, and Comorbidity-Burdened Patients With mCSPC
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top